Westfield Capital Management
AGIO icon

Westfield Capital Management’s Agios Pharmaceuticals AGIO Stock Holding History

Westfield Capital Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-479,750
Closed -$23.9M – 237
2019
Q2 		$23.9M Buy
479,750
+137,070
+40% +$7.33M 0.18% 160
2019
Q1 		$23.1M Buy
+342,680
New +$20M 0.18% 162

Other funds holding AGIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Westfield Capital Management's AGIO Position: Q3 2019 in Review

Westfield Capital Management sold out of Agios Pharmaceuticals (AGIO) in Q3 2019, closing a stake of 479,750 shares — an estimated $23.9M sold.

Westfield Capital Management first reported a position in AGIO in Q1 2019 and held it in 2 quarters. The position peaked at $23.9M in Q2 2019. 189 funds tracked by Wall St. Rank hold AGIO as of Q3 2019.

  • Westfield Capital Management reported no remaining Agios Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Westfield Capital Management sold 479,750 Agios Pharmaceuticals shares in Q3 2019, an estimated $23.9M.
  • Westfield Capital Management first reported a position in Agios Pharmaceuticals in Q1 2019 and held it in 2 quarters.
  • Westfield Capital Management's Agios Pharmaceuticals position peaked at $23.9M in Q2 2019.
  • 189 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2019.

Based on Westfield Capital Management's 13F filing for Q3 2019, filed 8 Nov 2019.